AstraZeneca Strengthens AI Partnership with Tempus in Oncology

Key Takeaways

1AstraZeneca plans to strengthen its partnership with Tempus around an AI project in oncology

2The goal is to develop an artificial intelligence model applied to cancer

3This collaboration is part of a growing trend of partnerships between science and AI, amplified by the rise of generative AI since ChatGPT

Why it matters : This partnership illustrates the increasing interest of companies in generative AI within the field of medical research.

AstraZeneca has decided to strengthen its ties with Tempus around an artificial intelligence project dedicated to oncology. This decision comes as collaborations between laboratories and AI technologies are multiplying, and generative AI is gaining traction since the arrival of ChatGPT.

Decision to Strengthen and Focus on an AI Model in Oncology

AstraZeneca plans to enhance an existing partnership with Tempus. The announced goal is to develop an artificial intelligence model applied to oncology. The two companies, AstraZeneca and Tempus, are thus collaborating on a cancer-focused project.

Le brief IA que lisent les pros

Le brief IA que les pros lisent chaque soir

Les 7 actus IA du jour, décryptées en 5 min. Gratuit.

Inclus dès l'inscription : notre sélection des meilleurs guides & comparatifs IA.

Choisissez votre rythme

Gratuit · Pas de spam · Désabonnement en 1 clic

A Movement Driven by the Democratization of Generative AI

This initiative is part of a trend where exchanges, partnerships, and the pooling of work between artificial intelligence and science have been developing for several years. The rise of generative AI, particularly since the arrival of ChatGPT, has prompted some international companies to take a greater interest in it.

Brief IA — L'actualité IA en français

L'essentiel de l'actualité de l'intelligence artificielle, décrypté et expliqué chaque jour.

Voir toutes les actus IA →